Lantheus (NASDAQ:LNTH) Stock Price Down 2.2% – What’s Next?

Lantheus Holdings, Inc. (NASDAQ:LNTH) shares fell 2.2% on Friday . The stock traded as low as $89.62 and last traded at $89.96. 363,405 shares changed hands during mid-day trading, a decline of 64% from the average session volume of 1,011,764 shares. The stock had previously closed at $91.94.

Analysts Set New Price Targets

Several equities analysts have commented on LNTH shares. Truist Financial reiterated a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday. They issued a “buy” rating and a $143.00 price target for the company. StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities dropped their target price on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday, November 7th. Finally, Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Stock Down 2.9 %

The stock has a market cap of $6.21 billion, a P/E ratio of 14.86 and a beta of 0.45. The business has a 50 day moving average price of $96.17 and a 200 day moving average price of $98.34.

Institutional Trading of Lantheus

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB purchased a new position in Lantheus in the 3rd quarter worth about $25,000. Signaturefd LLC increased its position in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares during the period. UMB Bank n.a. raised its stake in shares of Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares in the last quarter. Kathleen S. Wright Associates Inc. purchased a new stake in shares of Lantheus in the third quarter valued at approximately $51,000. Finally, GAMMA Investing LLC grew its stake in Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock worth $51,000 after purchasing an additional 146 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.